XSTOGABA
Market cap847kUSD
Dec 23, Last price
0.40SEK
1D
-1.25%
1Q
-35.88%
Jan 2017
-99.11%
IPO
-97.89%
Name
Gabather AB
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.89%
Rev. gr., 5y
-52.95%
Revenues
0k
Net income
-9m
L+10.44%
CFO
-12m
L+21.32%
Profile
Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was incorporated in 2014 and is based in Södertälje Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 4,518 | 12,362 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (4,518) | (12,362) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | (3) | 4 | ||||||||
Tax Rate | ||||||||||
NOPAT | (4,515) | (12,366) | ||||||||
Net income | (9,437) 10.44% | (8,545) -49.73% | (16,999) 15.29% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 8,466 | 1,022 | 46 | |||||||
BB yield | -41.55% | -1.66% | -0.08% | |||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 183 | |||||||||
Net debt | (1,165) | (6,322) | (14,897) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (11,643) | (9,597) | (16,117) | |||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | 6,486 | 1,022 | 46 | |||||||
FCF | 3,991 | (4,515) | (12,366) | |||||||
| Balance | ||||||||||
Cash | 1,115 | 6,272 | 14,847 | |||||||
Long term investments | 50 | 50 | 50 | |||||||
Excess cash | 1,165 | 6,322 | 14,897 | |||||||
Stockholders' equity | (113,826) | (104,861) | (96,411) | |||||||
Invested Capital | 114,312 | 108,299 | 107,375 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 14,451 | 13,604 | 13,407 | |||||||
Price | 1.41 -68.87% | 4.53 0.00% | 4.53 -19.11% | |||||||
Market cap | 20,376 -66.94% | 61,627 1.47% | 60,733 -19.09% | |||||||
EV | 19,211 | 55,305 | 45,836 | |||||||
EBITDA | (4,518) | (12,362) | ||||||||
EV/EBITDA | ||||||||||
Interest | 3 | 4 | ||||||||
Interest/NOPBT | ||||||||||